PMID: 9662265Jul 14, 1998Paper

Non-cryopreserved peripheral blood stem cells autotransplants for hematological malignancies can be performed entirely on an outpatient basis

American Journal of Hematology
G J Ruiz-ArgüellesJ L Delgado-Lamas

Abstract

We have prospectively performed peripheral blood stem cell autotransplants in six patients with hematological malignancies on an entirely outpatient basis. Patients were conditioned with high-dose melphalan and received a median of 4.2 x 10(8)/kg non-cryopreserved, non-purged mononuclear cells, containing a median of 3.9 x 10(6)/kg CD34 + cells. The median time to achieve > 500 granulocytes/microl was 21 days, with a range of 16 to 40, whereas the median time to achieve > 20,000 platelets/microl was 38 days, with a range of 21 to 48. Only three patients were transfused with platelets whereas packed red blood cells were transfused in two. All patients survived 60 days after the autograft and three are alive at 450, 690, and 1,950 days after the autotransplant. One patient was given an allogeneic bone marrow transplant when relapsing after the autotransplant. One patient had to be admitted to the hospital on day +10 because of fever. A median of 6,500.00 USD per patient was calculated as the total cost of each outpatient autotransplant. Since outpatient autologous transplants with non-frozen PBSC are feasible, restrictions to PBSC autotransplant programs may be overcome and costs may be diminished.

References

Aug 1, 1995·American Journal of Hematology·G J Ruiz-ArgüellesA Ruiz-Argüelles
Mar 24, 1994·The New England Journal of Medicine·J O Armitage
May 1, 1993·Anti-cancer Drugs·J H Scarffe
Mar 1, 1996·European Journal of Haematology·G J Ruiz-ArgüellesA Ruiz-Argüelles

❮ Previous
Next ❯

Citations

Jan 1, 2010·Mediterranean Journal of Hematology and Infectious Diseases·Guillermo J Ruiz-DelgadoGuillermo J Ruiz-Argüelles
Apr 8, 2009·Bone Marrow Transplantation·A López-OteroG J Ruiz-Argüelles
Apr 3, 2001·American Journal of Hematology·G J Ruiz-ArgüellesJ C Jaime-Pérez
Mar 27, 2012·Hematology/oncology and Stem Cell Therapy·M-A BekadjaF Attaf
Mar 31, 2015·BioMed Research International·Elva Jiménez-HernándezJuan Manuel Mejía-Aranguré
Mar 11, 2004·Archives of Medical Research·Guillermo J Ruiz-ArgüellesLeticia Aguilar-Romero
Jan 14, 2018·Bone Marrow Transplantation·Amado Kardduss-UruetaGuillermo J Ruiz-Argüelles
Jun 16, 2010·Bone Marrow Transplantation·T SchroederG Kobbe
Feb 25, 2018·Bone Marrow Transplantation·Robert Peter Gale, Guillermo J Ruiz-Argüelles
Aug 23, 2005·Bone Marrow Transplantation·G J Ruiz-ArgüellesC Manzano
May 29, 2007·Bone Marrow Transplantation·O G Cantú-RodríguezD Gómez-Almaguer
Nov 15, 2002·International Journal of Hematology·Guillermo J Ruiz-Argüelles
Mar 8, 2005·British Journal of Community Nursing·Louise Ritchie
Aug 16, 2002·Clinical and Laboratory Haematology·D Gómez-AlmaguerJ C Jaime-Pérez
Apr 27, 2020·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·S JennaneK Doghmi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.